Analysts are intrested in these 5 stocks: ( (QBTS) ), ( (SRPT) ), ( (CDNS) ), ( (ALB) ) and ( (CYBR) ). Here is a breakdown of their recent ratings and the rationale behind them.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
D-Wave Quantum is making waves in the quantum computing market with its unique approach to quantum annealing. Analyst Kevin Garrigan has initiated coverage with a Buy rating and a 12-month price target of $30. Garrigan highlights D-Wave’s first-mover advantage in quantum annealing, which offers significant benefits over classical and gate-based quantum systems for optimization tasks. The company’s dual-track roadmap, which includes both quantum annealing and gate-model systems, positions it well for capturing a substantial market share. With a projected revenue growth of 66% CAGR from 2025 to 2030, D-Wave’s commercial customer base and potential government opportunities are expected to drive long-term stock price appreciation.
Sarepta Therapeutics is experiencing mixed sentiments from analysts following the FDA’s decision to lift the voluntary hold on Elevidys for ambulatory patients. Anupam Rama from J.P. Morgan has upgraded the stock to Hold with a $24 price target, citing the regulatory win as a positive development. However, Rama expresses caution about the product launch curve and potential headline risks. On the other hand, Andreas Argyrides from Oppenheimer has upgraded Sarepta to Buy with a $37 price target, viewing the FDA’s decision as a major relief and expecting the stock to trade higher. William Pickering from Bernstein remains skeptical, initiating coverage with a Hold rating and a $13 price target, highlighting the uncertainty surrounding Elevidys and Sarepta’s financial obligations.
Cadence Design Systems has been downgraded to Neutral by analyst Clarke Jeffries from Piper Sandler, with a price target of $350. Despite strong quarterly results and robust growth in its core EDA and other segments, Jeffries believes the stock’s valuation has become less attractive. The company’s shares have risen significantly, pushing the valuation to approximately 45x CY26 P/E. While Cadence continues to demonstrate its essential role in the semiconductor value chain, the analyst suggests that the current price already reflects strong growth expectations, making it challenging to forecast further growth without significant changes in semiconductor market demand.
Albemarle, a leading specialty chemical company, faces challenges as analysts express concerns about the sustainability of recent lithium price increases. Ben Kallo from Baird has downgraded the stock to Sell with a $60 price target, citing speculator-driven price increases and potential risks to contract renegotiations. The analyst fears that the lower-for-longer pricing environment may persist, impacting Albemarle’s long-term supply/demand balance. Aleksey Yefremov from KeyBanc has also downgraded Albemarle to Sector Weight, noting that while lithium demand remains strong in the long term, the recent rally presents an opportunity to reduce risk. The analyst expects lithium prices to remain in the $8.50-$9.50/kg range in the near term.
CyberArk Software is in the spotlight following the announcement of its acquisition by Palo Alto Networks for approximately $25 billion. Several analysts, including Shrenik Kothari from Baird and Gray Powell from BTIG, have downgraded CyberArk to Hold, reflecting the acquisition terms. The deal, which offers $45 in cash and 2.2005 shares of PANW stock per CYBR share, represents a significant premium to CyberArk’s pre-deal share price. While the acquisition is seen as a positive outcome for CyberArk shareholders, analysts express uncertainty about the integration of CyberArk’s identity platform into Palo Alto’s broader strategy. The acquisition is expected to close in the second half of Palo Alto’s FY26, subject to customary closing conditions.